Product

Maytox 300

Trade name: MAYTOX Botulinum toxin type A
Group name: Botulinum toxin type A
Ingredient: Each bottle contains 500 units of Botulinum Toxin Type A. It contains 125 mcg of human serum albumin and 2.5mg of lactose monohydrate. Molecular Weight: 500-900 kDa
Target Protein: SNAP-25
Method of Preparation: Reconstitute with 0.9% Sodium Chloride Injection, USP
Usage: Intramuscular Use
Dosage Form: Lyophilized for solution for injection.
Typical: MAYTOX Botulinum toxin type A, in complex, lyophilisate for solution for intramuscular administration is a purified and freeze-dried botulinum toxin type A isolated from Clostridium botulinum type A in complex.
Indications for use: Blepharospasm in adults, upper extremity muscle spasticity after ischemic stroke in adults, correction of hyperkinetic facial folds (mimic wrinkles) in adults, spasticity of upper and lower extremity muscles in children 2-17 years of age with cerebral palsy, axillary hyperhidrosis in adults, cervical dystonia (spastic torticollis) in adults, chronic migraine in adults.
* The efficacy and safety of the treatment of quadriceps spasticity in cerebral palsy in children under 7 years of age have not been studied.
Contraindications: Widespread:
- up to 2 years of age for the indication "spasticity of the upper and lower extremities in children 2-17 years of age with cerebral palsy";
- up to 18 years for other indications (efficacy and safety not established);
- age up to 7 years for the indication "lower extremity spasticity with predominantly quadriceps femoris involvement" (efficacy and safety not established);
- inflammation at the proposed injection site;
- acute phase of infectious and non-communicable diseases;
- hypersensitivity to the components of the drug;
- increased body temperature;
- Pregnancy and lactation.
Correction of blepharospasm and mimic wrinkles:
- pronounced gravitational ptosis of facial tissues;
- pronounced hernia of the upper and lower eyelids;
- Less than 3 months after facial surgery.
Correction of wrinkles in the upper third of the face:
Myasthenia gravis or Lambert-Eaton syndrome.
Store between 2 and 8 (36-46F). Read the package insert for dosage and dilution information.

Maytox 500

Trade name: MAYTOX Botulinum toxin type A
Group name: Botulinum toxin type A
Ingredient: Each bottle contains 300 units of Botulinum Toxin Type A. It contains 125 mcg of human serum albumin and 2.5mg of lactose monohydrate.
Molecular Weight 500-900 kDa
Target Protein: SNAP-25
Method of Preparation: Reconstitute with 0.9% Sodium Chloride Injection, USP.
Usage: Intramuscular Use
Dosage Form: Lyophilized for solution for injection.
Typical: MAYTOX Botulinum toxin type A, in complex, lyophilisate for solution for intramuscular administration is a purified and freeze-dried botulinum toxin type A isolated from Clostridium botulinum type A in complex.
Indications for use: Blepharospasm in adults, upper extremity muscle spasticity after ischemic stroke in adults, correction of hyperkinetic facial folds (mimic wrinkles) in adults, spasticity of upper and lower extremity muscles in children 2-17 years of age with cerebral palsy, axillary hyperhidrosis in adults, cervical dystonia (spastic torticollis) in adults, chronic migraine in adults.
* he efficacy and safety of the treatment of quadriceps spasticity in cerebral palsy in children under 7 years of age have not been studied.
Contraindications: Widespread:
- up to 2 years of age for the indication "spasticity of the upper and lower extremities in children 2-17 years of age with cerebral palsy";
- up to 18 years for other indications (efficacy and safety not established);
- age up to 7 years for the indication "lower extremity spasticity with predominantly quadriceps femoris involvement" (efficacy and safety not established);
- inflammation at the proposed injection site;
- acute phase of infectious and non-communicable diseases;
- hypersensitivity to the components of the drug;
- increased body temperature;
- Pregnancy and lactation.
Correction of blepharospasm and mimic wrinkles:
- pronounced gravitational ptosis of facial tissues;
- pronounced hernia of the upper and lower eyelids;
- Less than 3 months after facial surgery.
Correction of wrinkles in the upper third of the face: Myasthenia gravis or Lambert-Eaton syndrome.
Store between 2 and 8 (36-46F). Read the package insert for dosage and dilution information.